Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 7/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9495292 | 0.85 | MAOA (0.47) | NT5EADORA2AADORA1IGF1RMAOA | |
| SCHEMBL4632695 | 0.83 | MAOA (0.45) | NT5EADORA2AADORA1IGF1RTLR7 | |
| SCHEMBL3300391 | 0.81 | BACE1 (0.66) | NT5EADORA2AADORA1IGF1RTLR7 | |
| SCHEMBL28311336 | 0.81 | ADORA2A (0.55) | NT5EADORA2AADORA1IGF1RTLR7 | |
| SCHEMBL19584409 | 0.80 | ADORA2A (0.51) | NT5EADORA2AADORA1IGF1RTLR7 | |
| SCHEMBL2425904 | 0.79 | ADORA2A (0.54) | NT5EADORA2AADORA1IGF1RTLR7 | |
| SCHEMBL423741 | 0.79 | CYP1A2 (0.58) | ADORA2AADORA1TLR7ADRB2BACE1 | |
| SCHEMBL30106738 | 0.79 | NCF1 (0.55) | NT5EADORA2AADORA1IGF1RTLR7 | |
| SCHEMBL2657337 | 0.79 | ADORA2A (0.54) | NT5EADORA2AADORA1IGF1RTLR7 | |
| SCHEMBL31473229 | 0.79 | CYP1A2 (0.58) | ADORA2AADORA1TLR7ADRB2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421823-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12479821-B2 | Quinoline compound and use thereof | MBD Co., Ltd. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2025-09-02 | — | — | US | disclosed |
| US-12384748-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | disclosed |
| US-12275707-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4499632-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2025-01-30 | — | — | US | disclosed |
| US-20250026735-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2025-01-23 | — | — | US | disclosed |
| EP-0847996-A1 | Sulfonamide substituted compounds as K-channel blockers | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-17 | — | — | EP | disclosed |
| EP-0317188-B1 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1995-09-27 | — | — | EP | disclosed |
| EP-0113432-B1 | CHLOROMETHYL QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | ALKALOIDA VEGYéSZETI GYáR (HU) | 1993-03-17 | — | — | EP | disclosed |
| US-5114940-A | Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides | ROUSSEL-UCLAF (FR) | 1992-05-19 | — | — | US | disclosed |
| EP-0317188-A2 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1989-05-24 | — | — | EP | disclosed |
| US-4267333-A | Preparation of 2-trifluoromethyl cinchoninic acids | UNION CARBIDE AGRICULTURAL PRODUCTS COMPANY, INC. (US) | 1981-05-12 | — | — | US | disclosed |
| US-4251661-A | Preparation of 2-trifluoromethyl cinchoninic acids | UNION CARBIDE CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4159331-A | Antihypertensive 4-aminoquinolines | THE UPJOHN COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4025629-A | HYPOTENSIVES, ANTIANXIETY | THE UPJOHN COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479821-B2 | Quinoline compound and use thereof | CYP4A11, CYP7A1, CYP4B1 | NT5E 3466/4885ADORA2A 2683/4885ADORA1 2705/4885 |
| US-12275707-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | NT5E 4611/4885ADORA2A 514/4885ADORA1 601/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | NT5E 3214/4885ADORA2A 1499/4885ADORA1 1152/4885 |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | NT5E 236/4885ADORA2A 216/4885ADORA1 163/4885 |
| US-20250026735-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | NT5E 4594/4885ADORA2A 455/4885ADORA1 520/4885 |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, IRF3 | NT5E 4594/4885ADORA2A 3358/4885ADORA1 4613/4885 |
| US-12384748-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | NT5E 4284/4885ADORA2A 287/4885ADORA1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.